TY - JOUR
T1 - Effectiveness of Ketorolac Tromethamine in Prevention of Severe Retinopathy of Prematurity.
AU - Papacci, Patrizia
AU - Molle, Fernando
AU - Lepore, Domenico
AU - Giannantonio, Carmen
AU - Purcaro, Velia
AU - Cota, Francesco
AU - Baldascino, Antonio
AU - Romagnoli, Costantino
AU - 33186,
AU - FACOLTA', DI MEDICINA E CHIRURGIA "A.GEMELLI"
AU - senso, ROMA - Dipartimento Testa-collo e organi di
AU - 33190,
AU - FACOLTA', DI MEDICINA E CHIRURGIA "A.GEMELLI"
AU - pubblica, ROMA - Dipartimento di Scienze della vita e sanità
AU - FACOLTA', DI MEDICINA E CHIRURGIA "A.GEMELLI"
AU - Tesfagabir, Ghennet
PY - 2010
Y1 - 2010
N2 - BACKGROUND:This study assessed the effectiveness of the use of ketorolac
tromethamine to reduce retinopathy of prematurity (ROP) incidence and its
progression to more severe forms. METHODS:Forty-seven preterm newborn infants
with a birth weight (BW) of 1,000 grams or less and/or a gestational age (GA) of
29 weeks or less were enrolled in the study when avascular retina zone I or ROP
any stage were diagnosed at screening. Studied infants were randomized to receive
ketorolac tromethamine ophthalmic solution in one eye and a drop of placebo in
the other eye, until ROP requiring treatment or full retinal vascularization was
diagnosed. RESULTS:Only 2 newborn infants did not develop ROP. Among 45 newborn
infants who developed ROP, 6 showed different ROP staging between the two eyes, 4
of which had a better outcome in the eye receiving ketorolac tromethamine. The
differences between ROP stagings were not significant even when analyzed by GA
and BW subgroups. No significant treatment-related side effects occurred.
CONCLUSION:This report suggests that ketorolac tromethamine ophthalmic solution
cannot reduce the risk of developing severe ROP in preterm infants.
AB - BACKGROUND:This study assessed the effectiveness of the use of ketorolac
tromethamine to reduce retinopathy of prematurity (ROP) incidence and its
progression to more severe forms. METHODS:Forty-seven preterm newborn infants
with a birth weight (BW) of 1,000 grams or less and/or a gestational age (GA) of
29 weeks or less were enrolled in the study when avascular retina zone I or ROP
any stage were diagnosed at screening. Studied infants were randomized to receive
ketorolac tromethamine ophthalmic solution in one eye and a drop of placebo in
the other eye, until ROP requiring treatment or full retinal vascularization was
diagnosed. RESULTS:Only 2 newborn infants did not develop ROP. Among 45 newborn
infants who developed ROP, 6 showed different ROP staging between the two eyes, 4
of which had a better outcome in the eye receiving ketorolac tromethamine. The
differences between ROP stagings were not significant even when analyzed by GA
and BW subgroups. No significant treatment-related side effects occurred.
CONCLUSION:This report suggests that ketorolac tromethamine ophthalmic solution
cannot reduce the risk of developing severe ROP in preterm infants.
KW - Ketorolac Tromethamine
KW - Ketorolac Tromethamine
UR - http://hdl.handle.net/10807/23113
M3 - Article
SP - 1
EP - 5
JO - Journal of Pediatric Ophthalmology and Strabismus
JF - Journal of Pediatric Ophthalmology and Strabismus
SN - 0191-3913
ER -